Long-term Therapeutic Outcome and Prognostic Factors of Patients with Nasopharyngeal Carcinoma Receiving Intensity-modulated Radiotherapy: An Analysis of 608 Patients from Low-endemic Regions of China
Overview
Authors
Affiliations
Objective: To evaluate the long-term outcome and prognostic factors of patients with nasopharyngeal carcinoma (NPC) from low-endemic regions of China who received definitive intensity-modulated radiation therapy (IMRT).
Methods: The clinical data from 608 patients with newly-diagnosed non-metastatic NPC who have received initial treatment at our cancer center from January, 2008 to December, 2013 were retrospectively reviewed. All patients received definitive IMRT, and 87.7% received platinum-based chemotherapy.
Results: The median follow-up duration was 51 months (follow-up rate, 98.5%; range, 10-106 months) for the entire cohort. The 5-year overall survival rate was 79.7%. The 5-year local relapse-free survival rate, regional relapse-free survival rate, distant metastasis-free survival rate and progression-free survival rate were 92.4%, 93.3%, 79.2% and 74.3%, respectively. A total of 153 patients had experienced treatment failure, with distant metastasis as the primary cause in 77.1% (118/153). Patients with T4 or N3 diseases had a significantly poorer prognosis than other subcategories. Stage T4 and N3 were closely associated with distant metastasis, with the metastatic rate of 29.3% and 45.5%, respectively.
Conclusion: IMRT provides patients with non-metastatic NPC with satisfactory long-term survival. Both T stage and N stage are important prognostic factors for NPC patients. Patients with T4 or N3 diseases have significantly increased distant metastatic rates and poor survival time.
Zheng Y, Xue F, Ou D, Niu X, Hu C, He X J Cancer Res Clin Oncol. 2025; 151(3):99.
PMID: 40035865 PMC: 11880137. DOI: 10.1007/s00432-025-06145-6.
Niu X, Xue F, Ou D, Zheng Y, Hu C, Shen C Int J Med Sci. 2025; 22(4):933-939.
PMID: 39991768 PMC: 11843132. DOI: 10.7150/ijms.105995.
Liu H, Lei L, Song S, Geng X, Lin K, Li N BMC Cancer. 2024; 24(1):1115.
PMID: 39244576 PMC: 11380781. DOI: 10.1186/s12885-024-12878-3.
Zheng Y, Xue F, Ou D, Niu X, Hu C, He X Cancer Med. 2024; 13(4):e6578.
PMID: 38457191 PMC: 10922019. DOI: 10.1002/cam4.6578.